Skip Navigation



International Immunology Advance Access published online on July 18, 2006
International Immunology, doi:10.1093/intimm/dxl069
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
18/9/1363    most recent
dxl069v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Polson, A. G.
Right arrow Articles by Ebens, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Polson, A. G.
Right arrow Articles by Ebens, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2006
Received December 7, 2005
Accepted June 20, 2006

Article

Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia

Andrew G. Polson 1 *, Bing Zheng 1, Kristi Elkins 1, Wesley Chang 2, Changchun Du 1, Patrick Dowd 1, Lulu Yen 3, Christine Tan 3, Jo-Anne Hongo 3, Hartmut Koeppen 2, and Allen Ebens 1

1 Department of Translational Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
2 Department of Pathology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
3 Department of Antibody Technology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

* To whom correspondence should be addressed.
Andrew G. Polson, E-mail: polson{at}gene.com


  Abstract

A new family of Ig domain receptors referred to as the immune receptor translocation-associated (IRTA) proteins, FcR homologs (FcRHs) or FcR-like that are expressed in lymphoid cells has been recently described. RNA expression analysis suggests that FcRH1-5/IRTA1-5 are expressed exclusively in subsets of the B-cell compartment. We generated mAbs to FcRH1-5/IRTA1-5 and examined their protein expression pattern in normal tissue and in chronic lymphocytic leukemia (CLL) cells. Our data indicated that FcRH1-5/IRTA1-5 were expressed in B-cell sub-populations; however, in some cases, the protein was not expressed in the same B-cell populations as suggested by the RNA expression analysis. FcRH1/IRTA5 was expressed throughout the B-cell lineage starting at the pro-B-cell stage but was down-regulated in plasma cells. FcRH2/IRTA4 was expressed preferentially in memory B cells. FcRH3/IRTA3 was expressed at low levels in naive, germinal center (GC) and memory B cells but was also expressed in NK cells. FcRH4/IRTA1 was expressed in a sub-population of memory B cells associated with mucosal tissue. FcRH5/IRTA2 was expressed in mature B cells and memory B cells and down-regulated in GC cells and, unlike all other B-cell-specific markers, maintained its expression in plasma cells from tonsil, spleen and bone marrow. We examined the expression of FcRH1-5/IRTA1-5 on the surface of CLL cells and found a similar pattern of expression on CLL cells as in the normal mature B cells, except for FcRH3/IRTA3 which was up-regulated in CLL.

Keywords: chronic lymphocytic leukemia; Fc receptor homologs; Fc receptor-like; FcRL; immunoreceptor translocation associated; memory B cells; NK cells.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Nagata, T. Ise, and I. Pastan
Fc Receptor-Like 3 Protein Expressed on IL-2 Nonresponsive Subset of Human Regulatory T Cells
J. Immunol., June 15, 2009; 182(12): 7518 - 7526.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. G. Polson, J. Calemine-Fenaux, P. Chan, W. Chang, E. Christensen, S. Clark, F. J. de Sauvage, D. Eaton, K. Elkins, J. M. Elliott, et al.
Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
Cancer Res., March 15, 2009; 69(6): 2358 - 2364.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
G. R.A. Ehrhardt, A. Hijikata, H. Kitamura, O. Ohara, J.-Y. Wang, and M. D. Cooper
Discriminating gene expression profiles of memory B cell subpopulations
J. Exp. Med., August 4, 2008; 205(8): 1807 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. J. Li, S. Ding, J. Pan, M. A. Shakhmatov, E. Kashentseva, J. Wu, Y. Li, S.-j. Soong, N. Chiorazzi, and R. S. Davis
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia
Blood, July 1, 2008; 112(1): 179 - 187.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Du, S. Nagata, T. Ise, M. Stetler-Stevenson, and I. Pastan
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins
Blood, January 1, 2008; 111(1): 338 - 343.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. G. Polson, S.-F. Yu, K. Elkins, B. Zheng, S. Clark, G. S. Ingle, D. S. Slaga, L. Giere, C. Du, C. Tan, et al.
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma
Blood, July 15, 2007; 110(2): 616 - 623.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. L. Haga, G. R. A. Ehrhardt, R. J. Boohaker, R. S. Davis, and M. D. Cooper
Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment
PNAS, June 5, 2007; 104(23): 9770 - 9775.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.